Overview

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Inserting genetic material made in the laboratory into a person's blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy and gene therapy in treating children who have recurrent or refractory neuroblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Aldesleukin
Ganciclovir
Ganciclovir triphosphate